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Abstract
Background: The accurate prognosis for patients with resectable pancreatic adenocarcinomas requires the incorporation of more factors 
than those included in AJCC TNM system.
Methods: We identified 218 patients diagnosed with stage I and II pancreatic adenocarcinoma at NewYork-Presbyterian Hospital/
Columbia University Medical Center (1999 to 2009). Tumor and clinical characteristics were retrieved and associations with survival 
were assessed by univariate Cox analysis. A multivariable model was constructed and a prognostic score was calculated; the prognostic 
strength of our model was assessed with the concordance index.
Results: Our cohort had a median age of 67 years and consisted of 49% men; the median follow-up time was 14.3 months and the 5-year 
survival 3.6%. Age, tumor differentiation and size, alkaline phosphatase, albumin and CA 19-9 were the independent factors of the final 
multivariable model; patients were thus classified into low (n = 14, median survival = 53.7 months), intermediate (n = 124, median 
survival = 19.7 months) and high risk groups (n = 80, median survival = 12.3 months). The prognostic classification of our model remained 
significant after adjusting for adjuvant chemotherapy and the concordance index was 0.73 compared to 0.59 of the TNM system.
Conclusion: Our prognostic model was accurate in stratifying patients by risk and could be incorporated into clinical decisions.
Keywords: pancreatic adenocarcinomas, prognosis, survival, multivariable modelBotsis et al
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Introduction
Pancreatic cancer (PC) is estimated to be the fourth 
leading fatal malignancy for 2009 in US and survival 
has not improved substantially over the past 30 years.1 
Pancreatic adenocarcinoma is the most common malig-
nancy of pancreas2 and has the worst prognosis among 
all.3 Surgical resection remains the gold standard of 
care, however only 15%–20% of PC patients are candi-
dates for curative resection.4 Prognosis for early stage 
patients remains poor3,5 with 5-year survival rates of 
25%–30% and 10% for surgically treated lymph node 
negative and positive patients respectively.4
According  to  the American  Joint  Committee  on 
Cancer  (AJCC)  TNM  Staging  System  (6th  edition, 
2002) a primary pancreatic tumor is considered resect-
able  when  limited  to  the  pancreas  and/or  extend-
ing beyond it but without involvement of the celiac 
axis or the superior mesenteric artery (T1, T2 and T3 
pathology staging).6 Adjuvant chemotherapy has been 
shown to improve the outcome of patients with local-
ized  pancreatic  adenocarcinoma  in  two  multicenter 
randomized clinical trials;7,8 however, the most effec-
tive chemotherapy regimens and the role of radiation 
and/or chemo-radiation therapy remain unclear.9 The 
National Cancer Institute (NCI) states that the avail-
able data does not resolve the controversy of the opti-
mal adjuvant therapy strategy and suggests that radical 
pancreatic  resection  may  or  may  not  be  combined 
with postoperative 5-FU chemotherapy and radiation 
therapy.10 Tumour size, lymph node involvement and 
differentiation have been also reported as the strongest 
predictors of long-term survival for resected (as this is 
defined by AJCC) pancreatic adenocarcinoma.11–13
TNM system does not incorporate prognostic vari-
ables other than those defining the TNM stages and fac-
tors that could potentially contribute to a more accurate 
prognostic classification are thus neglected. Here we 
developed a multivariable prognostic model for resect-
able pancreatic adenocarcinomas investigating a wide 
range of clinical and pathological factors.
Materials and Methods
Cohort description and data extraction
Cases of pancreatic adenocarcinomas diagnosed between 
January 1999 and January 2009 were retrospectively 
retrieved  from  the  NewYork-Presbyterian  Hospital/
Columbia University Medical Center (New York, NY) 
clinical data warehouse. A combination of clinical terms 
(pancreatic tumour and/or carcinoma, adenocarcinoma, 
Whipple,  pancreatectomy,  etc)  was  used  for  case 
identification;  the  extracted  records  were  manually 
reviewed to confirm their appropriateness for this study. 
Tumors arising in the duodenum or the peri-ampullary 
region, patient cases with undefined stage and patients 
that had received neo-adjuvant therapy before the sur-
gery (stage III at first diagnosis) were excluded; 218 
cases  of  resected  pancreatic  cancer  (stages  IA,  IB, 
IIA  and  IIB)  were  identified.  Patient  demographics 
(age at diagnosis, race, gender), tumor characteristics 
(localization, size, presence of lymph node metastasis, 
differentiation), personal medical history (history of 
other cancer, chronic pancreatitis, cholelithiasis, early 
onset diabetes mellitus) and history of cancer in first 
degree relatives, laboratory tests at diagnosis (aspartate 
aminotransferase-AST, alanine aminotransferase-ALT, 
alkaline  phosphatase-ALP,  albumin,  total  bilirubin) 
and tumor markers preoperatively (CA 19-9, carcino-
embryonic  antigen-CEA),  surgical  resection  (total- 
and distal-pancreatectomy and splenectomy, Whipple 
resection) are shown in Table 1. Patients were classi-
fied according to the AJCC TNM staging system and 
8 (4%) stage IA, 16 (7%) stage IB, 36 (17%) stage IIA 
and  158  (72%)  stage  IIB  tumours  were  identified 
(Table 1). The number of metastatic lymph nodes and 
their percentage over the harvested for the N1 patients 
are also shown in Table 1. This study was approved 
by  the  NewYork-Presbyterian  Hospital/Columbia 
University Medical Center Institutional Review Board 
and was conducted according to the ethical guidelines 
mandated by the Declaration of Helsinki.
statistical analysis
Differences between stages and other factors were 
investigated using the Kruskal-Wallis statistic for cat-
egorical and the t-test statistic for continuous variables. 
Disease-specific survival was defined as the time from 
diagnosis (evidenced in the pathology reports) to either 
death caused by disease or last follow-up. Univariate 
associations between demographics, clinical characteris-
tics, laboratory values, chemotherapy, surgical treatment 
and survival were assessed by Cox proportional hazards 
regression analysis; all variables that were significant 
at the 0.10 level were further analyzed in a multivari-
able Cox proportional hazards model. Age at diagno-
sis and size were analyzed as binary variables split by 
the median value and the 2 cm cut off point indicated resectable ductal adenocarcinomas prognosis
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by the TNM staging respectively. Laboratory values 
were  considered  either  as  normal  (within  reference 
range) or abnormal (2.5 times the upper limit for AST, 
ALT, ALP and total bilirubin; below lower limit for 
albumin; above 200 U/mL for CA 19-9 as suggested 
by Ferrone et al14 and above reference value for CEA). 
Clinically related variables were examined for interac-
tions prior to further analysis and the data set including 
the candidate variables identified in univariate analysis 
was imputed by applying the Multivariate Imputation 
by Chained Equations (MICE) method assuming that 
data were missing at random (MAR).15 Subsequently, 
1000 bootstrap samples were generated based on the 
imputed set and a backward elimination multivariable 
Cox  proportional  hazards  model  was  developed  for 
each bootstrap sample. The Akaike Information Cri-
terion (AIC) was used as the criterion for selection of 
the best prognostic model for a level of significance of 
0.05.16 The regression coefficients from the multivari-
able model were divided with the smallest coefficient 
in order to calculate a score (equal to the quotient of the 
division) for each variable, which was then weighted 
by its coefficient with zero points assigned to the refer-
ence category. Subsequently, the scores were summed 
up into a raw prognostic score and patients were strati-
fied into three risk groups using the tertiles as cut off 
points for risk classification. Survival curves for the 
risk groups were constructed using the Kaplan-Meier 
method and survival differences were analyzed by the 
log rank test. The prognostic strength of the model was 
compared to the TNM staging system using the concor-
dance index with 95% confidence intervals.17 P values 
were based on two-sided testing and differences were 
considered significant at p  0.05. All statistical analy-
ses were done in R-statistics software (version 2.9.1); 
the  Kaplan-Meier  curves  were  constructed  in  SPSS 
(version 15.0 for Windows, Chicago, IL).
Results
Patient characteristics
Two-hundred and eighteen patients diagnosed with 
early  stage  pancreatic  ductal  adenocarcinoma  who 
underwent  surgical  resection  were  identified;  our 
cohort consisted of 107 men (49%) and 111 women 
(51%)  with  a  median  age  of  64.0  (range:  42–86, 
mean ± SE: 64.0 ± 1.0) and 70.0 (36–88, mean ± SE: 
67.9 ± 1.0) respectively. One-hundred and sixty-seven 
(76.6%)  patients  were  white,  14  (6.4%)  black  and 
17 (7.8%) and 18 (8.3%) were of Hispanic and Asian 
origin respectively; race for two patients had not been 
recorded.  Thirteen  patients  (6%)  reported  family 
history of breast and/or ovarian cancer, and 11 (5%) 
of pancreatic cancer in first degree relatives; of the lat-
ter four patients reported a pair of affected first degree 
relatives. Thirty-three (15%) patients had personal his-
tory of cancer. The surgical treatment for the treatment 
of the primary tumor involved total pancreatectomy 
and splenectomy for 5 (3%), distal pancreatectomy 
and splenectomy for 24 (11%), and Whipple resection 
for 189 (86%) patients. One hundred and nine patients 
(50%) received adjuvant chemotherapy. The median 
length of follow up for all patients was 14.3 months 
(range: 0.7–118.7, mean ± SE: 18.5 ± 1.1) with a 
5-year, 3-year and 1-year disease specific survival of 
3.6%, 12.7% and 66.7% respectively.
Presence  of  nodal  metastases  was  identified  in 
157 (72.0%). The majority of adenocarcinomas arose 
in the head/neck (n = 184, 84.4%) and less in the body/
tail (n = 34, 15.6%). Nineteen (8.7%) of the tumors 
were poorly, 81 (37.2%) moderately and 111 (50.9%) 
well  differentiated;  differentiation  was  missing  for 
7  (3.2%)  cases.  There  was  no  difference  between 
stage I and stage II patients with respect to age (median 
age at diagnosis 69.5 years, range: 54–83, mean ± SE: 
68.3 ± 1.8 and 67.0 years, range: 36–88, mean ± SE: 
66.1 ± 0.8 respectively, p = 0.34), gender (p = 0.1), 
tumour differentiation (p = 0.67) or personal history 
of other cancer (p = 0.36). All clinical and pathologi-
cal characteristics are summarized in Table 1.
Identification of predictors of survival
Age at diagnosis over 67 years (HR: 1.83, 95% CI: 
1.33–2.50,  p    0.001),  presence  of  lymph  node 
metastasis (HR: 1.50, 95% CI: 1.05–2.16, p = 0.027), 
tumor size over 2 cm (HR: 1.89, 95% CI: 1.24–2.91, 
p  =  0.003)  and  personal  history  of  other  cancer 
(HR: 1.61, 95% CI: 1.04–2.51, p = 0.033; Table 2) were 
associated with worse prognosis; well and moderately 
differentiated tumors had significantly better outcome 
compared to poorly differentiated tumors (HR = 0.38, 
95% CI: 0.20–0.72, p = 0.003 and HR = 0.63, 95% 
CI:  0.45–0.89,  p  =  0.008  respectively;  Table  2). 
High levels of ALP (HR: 1.68, 95% CI: 1.09–2.59, 
p = 0.019), low levels of albumin (HR: 2.17, 95% CI: 
1.27–3.69, p = 0.004) and CA 19-9  200 U/mL (HR: 
1.53, 95% CI: 1.04–2.28, p = 0.033) were also poor Botsis et al
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Table 1. Cohort characteristics.
Variable no. of patients
Age at diagnosis
67 years 112
67 years 106
Race
White 167
Black 14
hispanic 17
Asian 18
not recorded 2
Gender
Female 111
Male 107
stage
stage IA 8
stage IB 16
stage IIA 36
stage IIB 158
pathology T
T1 13
T2 42
T3 163
pathology n
n0 61
n1 157
Metastatic lymph nodes*
3 80
3 75
Missing 2
percentage of metastatic 
lymph nodes*
25% 78
25% 77
Missing 2
Differentiation
Poor 111
Moderate 81
Well 19
Missing 7
Localization
Proximal pancreas 
(head/neck)
184
Distal pancreas (body/tail) 34
(Continued)
Table 1. (Continued)
Variable no. of patients
Tumour size
2 cm 41
2 cm 173
Missing 4
smoking
never 62
Former/Current 75
Missing 81
Alcohol
never 106
Former/Current 22
Missing 90
chronic pancreatitis
no 74
Yes 144
History of other cancer
no 149
Yes 33
Missing 36
cholelithiasis
no 190
Yes 28
Diabetes mellitus
no 124
Yes 60
Missing 34
AsT
normal 136
Abnormal 63
Missing 19
ALT
normal 135
high 69
Missing 14
Alkaline phosphatase
normal 174
Abnormal 31
not recorded 13
Albumin
normal 28
Abnormal 177
Missing 13
(Continued)resectable ductal adenocarcinomas prognosis
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with more than 3 infiltrated lymph nodes had worse 
prognosis (HR = 1.51, 95% CI: 1.04–2.19; Table 2). 
Whipple procedure was not associated with better out-
come compared to pancreatectomy (total or distal) and 
splenectomy (HR: 1.09, 95% CI: 0.66–1.82, p = 0.72; 
Table 2). TNM stages were associated with survival 
such that only patients with stage IIB had an increased 
risk compared to stage IA patients (HR = 3.39, 95% 
CI: 1.24–9.24, p = 0.017; Table 2). Survival rates were 
similar among patients with IA, IB and IIA disease 
(log rank p(IA vs. IB) = 0.125, log rank p(IA vs. IIA) = 0.056 
and log rank p(IB vs. IIA) = 0.718); also, differences were 
not observed between stage IIB and stage IIA (log 
rank p = 0.311) and IB (log rank p = 0.315) respec-
tively. However, the broader grouping of patients into 
stages I (n = 24) and II (n = 194) showed more distinct 
outcome with stage II patients having worse survival 
(HR = 1.82, 95% CI: 1.08–3.07, p = 0.025).
Development of a multivariable 
prognostic model
Variables significantly correlated with survival in uni-
variate analysis at a level of significance 0.10 were 
further  incorporated  in  a  multivariate  Cox  propor-
tional  hazards  regression  analysis  using  a  stepwise 
selection/backward  elimination  process  on  each  of 
the 1000 bootstrap samples. No interactions between 
the clinically related variables were observed. Age at 
diagnosis (HR = 1.40, 95% CI: 1.00–1.95, p = 0.045), 
tumor differentiation (HR = 0.65, 95% CI: 0.50–0.83, 
p    0.001),  size  (HR  =  1.72,  95%  CI:  1.11–2.67, 
p  =  0.016),  alkaline  phosphatase  (HR  =  1.59,  95% 
CI: 1.05–2.43, p = 0.029), albumin (HR = 2.35, 95% CI: 
1.38–4.03, p = 0.002), and CA 19-9 (HR = 1.49, 95% CI: 
1.05–2.11, p = 0.027) were the independent prognostic 
factors that were included in the final model (Table 3).
Based  on  the  factor  coefficients  we  developed 
a  prognostic  scoring  system  assigning  1  point  to 
age  over  67  years,  1.5  points  to  tumor  size  over 
2 cm, 1.5 points to high ALP, 1 point to CA 19-9 over 
200 U/mL, 2.5 points to low albumin, and −1.5 points 
and −3 points to moderately and well differentiated 
tumors respectively. All scores were summed up into 
a raw prognostic score and tertiles were used as cut 
off points to classify patients into three groups. Scores 
ranged from (−3)–0, 0.5–4 and 4.5–7.5 for the low 
(n = 14), intermediate (n = 124) and high (n = 80) risk 
groups respectively.
Table 1. (Continued)
Variable no. of patients
Total bilirubin
normal 169
Abnormal 36
Missing 13
cA 19-9
200 U/mL 112
200 U/mL 53
Missing 53
CeA
normal 89
high 77
Missing 52
chemotherapy
no adjuvant chemotherapy 109
Adjuvant chemotherapy 109
surgery
Pancreatectomy (distal or 
total) and splenectomy
29
Whipple procedure 189
Family history**
Breast, ovarian cancer 13 (1)
Pancreatic cancer 11 (4)
gastrointestinal (Other) 8 (0)
Other types 17 (3)
not contributory 52
Missing 122
*split at the median.
**At least 1st degree relative (pairs of 1st degree relatives in parenthesis).
prognostic factors. Additionally, black race had worse 
prognosis compared to the white race (HR: 1.94, 95% 
CI: 1.07–3.53, p = 0.029).
Univariate  analysis  showed  that  adjuvant  che-
motherapy  added  significant  benefit  to  the  disease 
outcome (HR: 0.45, 95% CI: 0.32–0.62, p  0.001; 
Table 2); there was no difference between stage I and 
stage II (n = 12 and n = 97, respectively; p = 0.99) 
or stage IA, IB, IIA and IIB (n = 3, n = 9, n = 17 and 
n = 80, respectively; p = 0.83) patients who received 
adjuvant  chemotherapy.  The  number  of  metastatic 
lymph nodes binarized by the median value (equals 3) 
and their percentage over the total number of harvested 
nodes (split at 25%) was further analyzed and patients Botsis et al
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Table 2. results of the Univariate Cox proportional hazards regression analysis.
Variable HR (95% cI) p-value
Age at diagnosis 0.001
67 years 1
67 years 1.83 (1.33–2.50)
Race 0.129
White 1
Black 1.94 (1.07–3.53) 0.029
hispanic 1.08 (0.58–2.01) 0.808
Asian 1.39 (0.80–2.42) 0.245
Gender 0.304
Female 1
Male 0.85 (0.62–1.16)
stage 0.069
stage IA 1
stage IB 2.41 (0.78–7.50) 0.128
stage IIA 2.72 (0.94–7.89) 0.065
stage IIB 3.39 (1.24–9.24) 0.017
pathology T 0.114
T1 1
T2 2.32 (1.03–5.21) 0.042
T3 2.20 (1.02–4.73) 0.044
pathology n 0.027
n0 1
n1 1.50 (1.05–2.16)
Metastatic lymph nodes* 0.029
3 1
3 1.51 (1.04–2.19)
percentage of metastatic lymph nodes* 0.151
25% 1
25% 1.31 (0.91–1.88)
Differentiation 0.001
Poor 1
Moderate 0.63 (0.45–0.89) 0.008
Well 0.38 (0.20–0.72) 0.003
Localization 0.768
Proximal pancreas (head/neck) 1
Distal pancreas (body/tail) 0.93 (0.59–1.47)
Tumour size 0.003
2 cm 1
2 cm 1.89 (1.24–2.91)
smoking 0.253
never 1
Former/Current 1.28 (0.84–1.94)
Alcohol 0.366
never 1
Former/Current 1.31 (0.73–2.35)
(Continued)resectable ductal adenocarcinomas prognosis
Cancer Informatics 2009:7  287
Table 2. (Continued)
Variable HR (95% cI) p-value
chronic pancreatitis 0.132
no 1
Yes 1.29 (0.93–1.80)
History of other cancer 0.033
no 1
Yes 1.61 (1.04–2.51)
cholelithiasis 0.296
no 1
Yes 0.77 (0.47–1.26)
Diabetes mellitus 0.509
no 1
Yes 1.13 (0.79–1.62)
AsT 0.282
normal 1
Abnormal 1.21 (0.85–1.72)
ALT 0.726
Abnormal 1
high 0.94 (0.67–1.33)
Alkaline phosphatase 0.019
normal 1
Abnormal 1.68 (1.09–2.59)
Albumin 0.004
normal 1
Abnormal 2.17 (1.27–3.69)
Total bilirubin 0.943
normal 1
Abnormal 1.02 (0.67–1.55)
cA 19-9 0.033
200 U/mL 1
200 U/mL 1.53 (1.04–2.28)
ceA 0.358
normal 1
high 1.19 (0.82–1.71)
chemotherapy 0.001
no adjuvant chemotherapy 1
Adjuvant chemotherapy 0.45 (0.32–0.62)
surgery 0.723
Pancreatectomy (distal or total) and 
splenectomy
1
Whipple procedure 1.09 (0.66–1.82)
*For patients with pathology n1 status.Botsis et al
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Patients in the low risk group had a better prognosis 
compared  to  patients  in  the  intermediate  (median 
survival 53.7 vs. 19.7 months, p = 0.005; Fig. 1A) and 
high risk group (median survival 53.7 vs. 12.3 months, 
p  0.001; Fig. 1A). Patients classified in the interme-
diate risk group showed a distinct benefit towards over-
all survival compared to patients of the high risk group 
(median  survival  19.7  vs.  12.3  months,  p    0.001; 
Fig. 1A). Interestingly 4 and 7 patients with IIA and IIB 
TNM disease respectively were classified in the low 
risk group whereas 7 stage IB patients were classified 
in the high risk group, underlying the weakness of the 
AJCC TNM system to accurately stratify patients by 
risk based on the tumor characteristics only (survival 
curves for AJCC TNM stages are shown in Fig. 1B). 
The concordance index calculated to assess the accuracy 
of our model was equal to 0.73 (95% CI: 0.58–0.84). 
The concordance index of the TNM staging system was 
equal to 0.59 (95% CI: 0.42–0.74) when patients were 
grouped into stages IA, IB, IIA and IIB and 0.62 (95% 
CI: 0.38–0.81) when they were classified into stages I 
and II.
Subsequently,  we  adjusted  our  final  model  for 
adjuvant chemotherapy by performing a second mul-
tivariable Cox proportional hazard analysis. The prog-
nostic stratification of our model (HR = 3.91, 95% 
CI: 1.72–8.85, p = 0.001 and HR = 9.37, 95% CI: 
4.02–21.83, p  0.001 for the intermediate and high 
risk groups respectively) and adjuvant chemotherapy 
(HR = 0.38, 95% CI: 0.27–0.53, p  0.001) were 
both significantly correlated with survival indicating 
that our prognostic classification is an independent 
predictor of outcome for resectable pancreatic ductal 
adenocarcinoma. The benefit of adjuvant chemother-
apy did not differ between low, intermediate and high 
risk patients who received chemotherapy treatment 
(n = 7, n = 66 and n = 36, respectively; p = 0.52).
Discussion
The  TNM  staging  system  classifies  patients  with 
exocrine pancreatic cancer according to their patho-
logic characteristics and distinguishes between local-
ized resectable (Stages I and II), locally advanced 
(Stage III) and metastatic disease (stage IV).6 The 
outcome for patients undergoing surgical resection 
cannot be accurately predicted based on the TNM 
classification alone highlighting the need for incor-
poration  of  other  parameters  in  such  systems.  We 
developed a robust multivariable model for stratify-
ing resectable pancreatic ductal adenocarcinomas by 
risk and compared its prognostic accuracy with the 
TNM staging system. Our model classified patients 
with higher accuracy compared to the TNM system; 
concordance  indexes  were  equal  to  0.73  and  0.59 
respectively.
Patients classified as stage II by the TNM system 
had a shorter survival compared to stage I patients 
(HR = 1.82, 95% CI: 1.08–3.07, p = 0.025), how-
ever the only significant pairwise comparison among 
TNM  subgroups  was  between  Stages  IA  and  IIB 
(p = 0.017; Fig. 1B). Survival rates among patients 
in any other subgroup did not differ significantly and 
this highlights the inherent weaknesses of the cur-
rent staging system. Our prognostic score stratified 
patients in three groups with clear outcome and sig-
nificant survival differences were found for all pair-
wise comparisons.
We found that ALP is an independent prognostic fac-
tor for resectable pancreatic ductal adenocarcinomas; 
this  has  not  been  shown  before  to  the  best  of  our 
Table 3. Multivariable analysis results of Cox proportional hazards regression model.
Variable Coefficient HR (95% cI) p-value
prognostic model
(AIC = 1373.749) Age at Diagnosis 0.338 1.40 (1.00–1.95) 0.045
Differentiation −0.435 0.65 (0.50–0.83)  0.001
Tumour size 0.543 1.72 (1.11–2.67) 0.016
Alkaline Phosphatase 0.467 1.59 (1.05–2.43) 0.029
Albumin 0.856 2.35 (1.38–4.03) 0.002
CA 19-9 0.397 1.49 (1.05–2.11) 0.027resectable ductal adenocarcinomas prognosis
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knowledge. ALP has been shown to be a significant 
independent factor for advanced pancreatic cancer18 
and that a 1.8-fold increase of ALP was associated with 
poor prognosis in a veterans’ cohort, independently of 
tumor stage.19 Serum albumin was strongly correlated 
with survival in our multivariable model; this is con-
sistent with the report of Schnelldorfer et al who found 
that preoperative low albumin was a negative predictor 
of survival in patients with pancreatic adenocarcinoma 
undergoing a Whipple procedure; however they failed 
to prove its independent prognostic value.3
We demonstrated that pre-operative CA 19-9 level 
above 200 U/mL was an important independent prog-
nostic factor. The selection of the cut off point was based 
on the study of Ferrone et al who examined CA 19-9 
levels as a prognostic factor for patients with resectable 
pancreatic adenocarcinoma and suggested 200 U/mL 
as the appropriate cut-off point.14 Additionally, recent 
studies showed that CA 19-9 elevation over the labora-
tory reporting limit (37 U/mL) may occur in patients 
without malignant disease.20,21 In light of these find-
ings and of our results we suggest the shift of the criti-
cal CA 19-9 values to a higher limit; 200 U/mL could 
be a reliable choice.
Tumor differentiation and size have been shown to be 
independent prognostic factors for patients with resect-
able pancreatic adenocarcinoma in various studies.2,13,22–25 
Nevertheless, only Winter et al followed the same AJCC 
criteria with us to define a pancreatic tumor as resect-
able.13 Also, the split for tumor size varied among these 
studies with the criterion of 2 cm being selected in two 
cases only.23,25 Age at diagnosis was included in our mul-
tivariable model and this is an important finding given 
the controversy around the prognostic potential of age 
for resectable ductal adenocarcinomas (summarized by 
Garcea et al).26
Patients receiving adjuvant chemotherapy had a 
clear survival benefit in both univariate and multi-
variate analyses in our population which is consistent 
with the findings of Neoptolemos et al7 and Oettle 
et al.8 The benefit was similar for all patients receiving 
adjuvant chemotherapy independently of their group-
ing into the TNM stages or our own groups. Most 
importantly our prognostic classification was inde-
pendent of adjuvant chemotherapy and this is the first 
report of such a model to the best of our knowledge.
Potential limitations of the current study are the 
retrospective nature of data collection and the impu-
tation of variables with missing values. Nevertheless, 
it should be mentioned that data imputation has been 
proven to be superior to both complete case analy-
sis  and  missing-indicator  method  in  multivariable 
diagnostic research27 and has been suggested as the 
ideal approach to address missingness in retrospective 
1A:  Our multivariable prognostic model 1B: TNM staging system
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Figure 1. Disease outcome by A) our multivariable model with low risk patients showing an exceptional benefit towards survival compared to intermediate 
(log rank p = 0.005) and high risk patients (log rank p  0.001); intermediate vs. high risk patients also have better outcome (log rank p  0.001) and B) the 
AJCC TnM staging system (log rank p(IA vs. IB) = 0.125, p(IA vs. IIA) = 0.056, p(IA vs. IIB)= 0.010, p(IB vs. IIA) = 0.718, p(IB vs. IIB) = 0.315 and p(IIA vs. IIB) = 0.311).Botsis et al
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analyses.28–30 Also, MICE method is indicated for the 
imputation of categorical variables with specific vari-
ables acting as predictors in this process.15
It could be also argued that the lack of validation 
with  an  external  independent  data  set  reduces  the 
impact of our work. However, the selected bootstrap 
resampling approach supports the construction of val-
idated predictive models, especially when it is com-
bined with automated variable selection methods.16,31 
Doubtless, the validation of our model in a prospec-
tively collected cohort could potentially establish it in 
clinical practice.
In conclusion, we developed an accurate multi-
variable prognostic model for resectable pancreatic 
ductal  adenocarcinomas,  incorporating  age,  tumor 
differentiation and size, preoperative CA 19-9, serum 
albumin and alkaline phosphatase. The AJCC TNM 
staging system that classifies patients based on tumor 
characteristics only was found to be inferior compared 
to our model. Our results indicate that the addition of 
prognostic factors other than the traditional tumor-
related ones could lead to a more accurate prognostic 
stratification  of  patients  with  resectable  pancreatic 
ductal adenocarcinoma. Such an approach could dra-
matically improve clinical decision-making.
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